Several small-cap biotech and therapeutics companies posted notable gains in Monday's after-hours trading session, driven by earnings updates, financial guidance, and regulatory developments.
Inotiv, Inc. (NOTV) surged 36.61% in after-hours trading to $0.94, recovering sharply from its steep 33.20% decline at the close. The rebound followed the company's preliminary fourth-quarter and full-year 2025 results. Inotiv anticipates Q4 revenue between $137.5 million and $138.5 million, while full-year revenue is projected between $512.5 million and $513.5 million.
Applied Therapeutics, Inc. (APLT) climbed 16.89% after hours to $0.33, extending gains from its 30.19% rally at the close. While no fresh news was released Monday, investors appear to be reacting positively to the company's November 13 earnings report, which showed a narrower Q3 net loss of $19.0 million, or $0.13 per share, compared to a $68.6 million loss, or $0.48 per share, in the prior year's quarter.
Alumis Inc. (ALMS) advanced 7.09% after hours to $5.97, building on its modest 1% gain at the close. The company recently reported a Q3 net loss of $110.8 million, wider than the $93.1 million loss in the same period last year. However, revenue included $2.1 million in collaboration income tied to its licensing agreement with Kaken Pharmaceutical Co., Ltd., which may have provided some investor confidence.
TELA Bio, Inc. (TELA) rose 7.89% after hours to $1.23, following a 14.08% gain at the close. The company's November 13 earnings report highlighted a reduced Q3 net loss of $8.6 million compared to $10.4 million a year earlier, alongside revenue growth of 9% to $20.7 million. TELA also revised its 2025 guidance, projecting at least 16% revenue growth over 2024. Additionally, the company announced a $13.0 million registered direct offering, expected to close on November 17, which may bolster its balance sheet.
Corcept Therapeutics Inc. (CORT) gained 4.90% after hours to $78.80, reversing its slight decline at the close. No company-specific news was released Monday, but the move reflects continued investor interest in the stock.
BioRestorative Therapies, Inc. (BRTX) jumped 8.06% after hours to $1.34, rebounding from a 6.77% decline at the close. The company announced it has been granted a Type B meeting with the U.S. Food and Drug Administration in mid-December to discuss a potential accelerated Biologics License Application pathway for its Fast-Track-Designated BRTX-100 program, aimed at treating chronic lumbar disc disease. The regulatory update appears to have fueled investor optimism.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.